Combination of H1 and H2 Histamine Receptor Antagonists: Current Knowledge and Perspectives of a Classic Treatment Strategy.

H1 receptor H2 receptor clinical application combination therapy histamine histamine receptor antagonists histamine-mediated diseases

Journal

Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444

Informations de publication

Date de publication:
23 Jan 2024
Historique:
received: 14 12 2023
revised: 19 01 2024
accepted: 20 01 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Histamine receptor antagonists, which can bind to specific histamine receptors on target cells, exhibit substantial therapeutic efficacy in managing a variety of histamine-mediated disorders. Notably, histamine H1 and H2 receptor antagonists have been extensively investigated and universally acknowledged as recommended treatment agents for numerous allergic diseases and acid-related disorders, respectively. Historically, the combination of H1 and H2 receptor antagonists has been considered a classic treatment strategy, demonstrating relatively superior efficacy compared with single-drug therapies in the treatment of diverse histamine-mediated diseases. The latest emerging studies have additionally suggested the underlying roles of histamine and H1R and H2R in the development of anxiety disorders, arthritic diseases, and postexercise hypotension. Nevertheless, there is still a lack of systematic reviews on the clinical efficacy of combination therapy, greatly limiting our understanding of its clinical application. Here, we present a comprehensive overview of the current knowledge and perspectives regarding the combination of H1 and H2 histamine receptor antagonists in various histamine-mediated disorders. Furthermore, we critically analyze the adverse effects and limitations associated with combination therapy while suggesting potential solutions. Our review can offer a systematic summary and promising insights into the in-depth and effective application of the combination of H1 and H2 receptor antagonists.

Identifiants

pubmed: 38398673
pii: life14020164
doi: 10.3390/life14020164
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Shanghai Collaborative Innovation Project
ID : XTCX-KJ-2023-44
Organisme : National Natural Science Foundation of China
ID : 32201251
Organisme : Basic scientific research project of Naval Medical University
ID : 2022MS009

Auteurs

Erwen Kou (E)

Department of Dermatology, Naval Medical Center, Naval Medical University, Shanghai 200052, China.

Xiaobei Zhang (X)

Department of Pharmacy, Naval Medical Center, Naval Medical University, Shanghai 200052, China.

Baiping Dong (B)

Department of Dermatology, Naval Medical Center, Naval Medical University, Shanghai 200052, China.

Bo Wang (B)

Department of Dermatology, Naval Medical Center, Naval Medical University, Shanghai 200052, China.

Yuanjie Zhu (Y)

Department of Dermatology, Naval Medical Center, Naval Medical University, Shanghai 200052, China.

Classifications MeSH